WO2003066829A3 - Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof - Google Patents

Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof Download PDF

Info

Publication number
WO2003066829A3
WO2003066829A3 PCT/US2003/003747 US0303747W WO03066829A3 WO 2003066829 A3 WO2003066829 A3 WO 2003066829A3 US 0303747 W US0303747 W US 0303747W WO 03066829 A3 WO03066829 A3 WO 03066829A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nucleic acids
well
discoveries
formation
Prior art date
Application number
PCT/US2003/003747
Other languages
French (fr)
Other versions
WO2003066829A2 (en
Inventor
Perry B Hackett
Aidas Nasevicius
Shannon Wadman
Jeffrey Essner
Jon Larson
Karl J Clark
Sharon Roberg-Perez
Stephen C Ekker
Original Assignee
Discovery Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discovery Genomics Inc filed Critical Discovery Genomics Inc
Priority to AU2003209054A priority Critical patent/AU2003209054A1/en
Publication of WO2003066829A2 publication Critical patent/WO2003066829A2/en
Publication of WO2003066829A3 publication Critical patent/WO2003066829A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Abstract

The application is related to the field of nucleic acids with identifed utility, and more particularly, to genes, related nucleic acids, their complements, polypeptides, and methods of using hte same for blood vessel, cartilage, and bone formation, as well as inhibition thereof. The application describes discoveries made using the zebrafish embryo technique, as well as other techniques that are described herein. The discoveries include genes, related nucleic acids, and their complements as, well as sequences, polypeptides, other molecules, and methods for using them, e.g., TDE1, PTV, MOESIN, and HKE4. Also described are polypeptide products, inhibition of expression, administration of materials and products, screening procedures, and techniques for making drugs. Moreover, uses of these discoveries in appropriate contexts are set forth.
PCT/US2003/003747 2002-02-07 2003-02-07 Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof WO2003066829A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003209054A AU2003209054A1 (en) 2002-02-07 2003-02-07 Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35497802P 2002-02-07 2002-02-07
US60/354,978 2002-02-07

Publications (2)

Publication Number Publication Date
WO2003066829A2 WO2003066829A2 (en) 2003-08-14
WO2003066829A3 true WO2003066829A3 (en) 2006-07-06

Family

ID=27734445

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/003747 WO2003066829A2 (en) 2002-02-07 2003-02-07 Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof

Country Status (3)

Country Link
US (1) US20030220249A1 (en)
AU (1) AU2003209054A1 (en)
WO (1) WO2003066829A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143557A (en) * 1995-06-07 2000-11-07 Life Technologies, Inc. Recombination cloning using engineered recombination sites
US7351578B2 (en) * 1999-12-10 2008-04-01 Invitrogen Corp. Use of multiple recombination sites with unique specificity in recombinational cloning
ATE341621T1 (en) * 1997-10-24 2006-10-15 Invitrogen Corp RECOMBINATORY CLONING USING NUCLIC ACIDS HAVING RECOMBINATION SITE
US20030124555A1 (en) * 2001-05-21 2003-07-03 Invitrogen Corporation Compositions and methods for use in isolation of nucleic acid molecules
AU774643B2 (en) 1999-03-02 2004-07-01 Invitrogen Corporation Compositions and methods for use in recombinational cloning of nucleic acids
US7198924B2 (en) 2000-12-11 2007-04-03 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2003273995A1 (en) * 2002-06-05 2003-12-22 Invitrogen Corporation Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites
AU2003257984A1 (en) * 2002-08-02 2004-02-23 Ohio University Diagnosis of kidney damage and protection against same
EP1697534B1 (en) 2003-12-01 2010-06-02 Life Technologies Corporation Nucleic acid molecules containing recombination sites and methods of using the same
GB2413847A (en) * 2004-04-26 2005-11-09 Daniolabs Ltd Bone disease models

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033979A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Bone marrow secreted proteins and polynucleotides
WO2000055350A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
ATE124999T1 (en) * 1985-03-15 1995-07-15 Antivirals Inc POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS.
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5449754A (en) * 1991-08-07 1995-09-12 H & N Instruments, Inc. Generation of combinatorial libraries
US5302397A (en) * 1991-11-19 1994-04-12 Amsden Brian G Polymer-based drug delivery system
US5503805A (en) * 1993-11-02 1996-04-02 Affymax Technologies N.V. Apparatus and method for parallel coupling reactions
US5891108A (en) * 1994-09-12 1999-04-06 Cordis Corporation Drug delivery stent
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
US6041252A (en) * 1995-06-07 2000-03-21 Ichor Medical Systems Inc. Drug delivery system and method
US5783397A (en) * 1995-12-11 1998-07-21 Northeastern University Screening natural samples for new therapeutic compounds using capillary electrophoresis
US6042789A (en) * 1996-10-23 2000-03-28 Glaxo Group Limited System for parallel synthesis of organic compounds
US5972027A (en) * 1997-09-30 1999-10-26 Scimed Life Systems, Inc Porous stent drug delivery system
US6083682A (en) * 1997-12-19 2000-07-04 Glaxo Group Limited System and method for solid-phase parallel synthesis of a combinatorial collection of compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999033979A2 (en) * 1997-12-30 1999-07-08 Chiron Corporation Bone marrow secreted proteins and polynucleotides
WO2000055350A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human cancer associated gene sequences and polypeptides
WO2001070979A2 (en) * 2000-03-21 2001-09-27 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and method for identification, assessment, prevention and therapy of ovarian cancer

Also Published As

Publication number Publication date
AU2003209054A8 (en) 2003-09-02
AU2003209054A1 (en) 2003-09-02
WO2003066829A2 (en) 2003-08-14
US20030220249A1 (en) 2003-11-27

Similar Documents

Publication Publication Date Title
Xu et al. Isolation and characterization of peptides from mytilus edulis with osteogenic activity in mouse MC3T3-E1 preosteoblast cells
WO2003066829A3 (en) Factors for angiogenesis, vasculogenesis, cartilage formation, bone formation and methods of use thereof
EP2650311A3 (en) Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
Feng et al. When MAGE meets RING: insights into biological functions of MAGE proteins
Himes et al. The role of high-mobility group I (Y) proteins in expression of IL-2 and T cell proliferation
BRPI0307237A2 (en) use of multi-layer pigments in the food and pharmaceutical sector
HUP0203256A2 (en) Process for producing a product containing antihypertensive tripeptides
WO2001012659A3 (en) Human dna sequences
WO2007115578A8 (en) Synthetic mecp2 sequence for protein substitution therapy
WO2008153745A3 (en) Compositions and methods for producing bioactive fusion proteins
EP2557090A3 (en) Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
Zheng et al. Peptides derived from sea cucumber accelerate cells proliferation and migration for wound healing by promoting energy metabolism and upregulating the ERK/AKT pathway
Ohtsuki et al. Optimal arrangement of four short DNA strands for delivery of immunostimulatory nucleic acids to immune cells
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
WO2005066344A3 (en) New plasmids, their derivatives and fragments, their methods of manufacture and application
Wang et al. Cloning and characterization of Adinbitor, a novel disintegrin from the snake venom of Agkistrodon halys brevicaudus stejneger
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
DE60042793D1 (en) INHIBITOR OF THE HEPATOCYTE GROWTH FACTOR ACTIVATOR AND ITS USE IN MODULATION OF ANGIOGENESIS AND HERB VASCULARIZATION
WO1999051723A3 (en) Bacterial transglutaminases
WO2007089950A3 (en) Preparations of growth hormone
BRPI0415703A (en) protein expression
JPS6277324A (en) Novel plasma and utilization thereof
Carron et al. Expression of members of the thrombospondin family by human skeletal tissues and cultured cells
Wallach et al. 12th international TNF conference: the good, the bad and the scientists
KR101785502B1 (en) A fusion protein of fibronectin protein and Bone morphogenetic protein-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP